We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
-$295M
Cap. Flow
-$688M
Cap. Flow %
-3.02%
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$58.8M
2
LEGN icon
Legend Biotech
LEGN
+$52.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$34M
4
JBIO
Jade Biosciences
JBIO
+$32.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.9M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$611M
2
NVTA
Invitae Corporation
NVTA
+$179M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$33.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$32.4M
5
ALT icon
Altimmune
ALT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
101
DELISTED
Acceleron Pharma
XLRN
$2.81M 0.01%
22,430
– –
TVTX icon
102
Travere Therapeutics
TVTX
$5.34B
$2.73M 0.01%
186,915
– –
RLMD icon
103
Relmada Therapeutics
RLMD
$557M
$2.45M 0.01%
+76,600
New +$2.66M
LOGC
104
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2M 0.01%
451,478
– –
TARA icon
105
Protara Therapeutics
TARA
$218M
$1.95M 0.01%
199,671
– –
INZY
106
DELISTED
Inozyme Pharma
INZY
$1.82M 0.01%
106,999
– –
PASG icon
107
Passage Bio
PASG
$14.6M
$1.55M 0.01%
5,858
-5,910
-50% -$1.83M
AFMD
108
DELISTED
Affimed
AFMD
$1.4M 0.01%
16,461
– –
OYST
109
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.06M ﹤0.01%
61,424
– –
CYPH
110
Cypherpunk Technologies Inc
CYPH
$65.4M
$918K ﹤0.01%
55,971
– –
BLCM
111
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$822K ﹤0.01%
249,123
– –
KZR
112
DELISTED
Kezar Life Sciences
KZR
$758K ﹤0.01%
13,968
– –
KRRO icon
113
Korro Bio
KRRO
$149M
$553K ﹤0.01%
1,111
– –
SYRS
114
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$357K ﹤0.01%
6,550
-62,467
-91% -$3.7M
AUTL
115
Autolus Therapeutics
AUTL
$386M
– –
-461,726
Closed -$2.65M
GLMD icon
116
Galmed Pharmaceuticals
GLMD
$4.46M
– –
-1,027
Closed -$634K
LKFT
117
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
– –
-11,180
Closed -$862K
GNFT
118
DELISTED
Genfit
GNFT
– –
-14,720
Closed -$68K
IFRX icon
119
InflaRx
IFRX
$253M
– –
-138,040
Closed -$538K
SGMO
120
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-429,063
Closed -$5.38M
SRPT icon
121
Sarepta Therapeutics
SRPT
$1.66B
– –
-58,700
Closed -$4.38M
VKTX icon
122
Viking Therapeutics
VKTX
$3.93B
– –
-363,980
Closed -$2.3M
XNCR icon
123
Xencor
XNCR
$1.48B
– –
-369,370
Closed -$15.9M
ACGN
124
DELISTED
Aceragen Inc
ACGN
– –
-120,543
Closed -$2.66M
MTEM
125
DELISTED
Molecular Templates, Inc.
MTEM
– –
-8,922
Closed -$1.69M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Baker Bros. Advisors held 135 positions worth $22.8B, down 1.3% from $23.1B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors withdrew a net $688M in Q2 2021, closing 15 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $611M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Verve Therapeutics worth $85.3M.

  • Baker Bros. Advisors's largest Q2 2021 buy was Verve Therapeutics: 1,416,530 shares worth $85.3M.
  • Baker Bros. Advisors added most to Legend Biotech in Q2 2021, an estimated $52.6M increase.
  • Baker Bros. Advisors's biggest Q2 2021 reduction was Invitae Corporation, cutting an estimated $179M.
  • Baker Bros. Advisors fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $611M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $22.8B portfolio in Q2 2021.
  • Baker Bros. Advisors opened 6 new positions and closed 15 in Q2 2021.
  • Baker Bros. Advisors's portfolio value fell 1.3% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.